抗精神病药长效针剂治疗精神分裂症的专家共识

Expert consensus on long-acting injectable in the treatment of schizophrenia

精神分裂症是一种慢性、高复发性和高致残性疾病,预防复发是治疗过程中的关键。国内外治疗指南中推荐抗精神病药长效针剂为预防复发的重要治疗策略之一,并且目前已积累一定的研究数据。由于治疗指南更新的相对滞后,针对长效针剂的实际临床应用尚不能及时在指南中全面体现。基于此,在中华医学会精神医学分会精神分裂症协作组的组织下,由15位精神科专家组成了本共识的专家组,在系统总结长效针剂在精神分裂症全程治疗中的疗效和安全性数据基础上,针对临床实践者最关注的长效针剂实际临床应用问题,包括适用患者人群、用法用量、临床应用、常见不良反应及处理、特殊人群使用以及使用全程中的医患沟通要点给予了合理阐述,以期帮助医生在实践中规范合理地应用以改善患者的治疗及预后。

Schizophrenia is a chronic,recurrent and disabling illness and prevention of relapse is the key to treatment.Long-acting injectable(LAI)is one of the most important treatment strategies to prevent relapse,as recommended by the international guidelines.And more evidences are published gradually in recent years.However,due to the delayed revision of treatment guidelines,short of specific suggestions for the practical clinical application of LAI are not full covered yet.Therefore,under the organization of the Chinese Schizophrenia Coordination Group(CSCG),15 psychiatrists formed the expert group members of this consensus.The expert group systematically reviewed and analyzed the up-to-date efficacy and safety data of LAI,and based on the evidence-based medicine data,gave expert suggestions on the practical clinical application of LAI.The consensus included the practical clinical application,for example,suitability for patients,usage and dosage,clinical application,common adverse reactions and treatment,use of special population,and doctor-patient communication of LAI.This consensus is helpful for optimizing the use of LAI and improring the outcome of patients with schizophrenia.